新股消息   眼科生物科技公司拨康视云四次递表港交所 2024年亏损约0.99亿美元

金融界
11 Jun

智通财经获悉,据港交所6月11日披露,CLOUDBREAK PHARMA INC.(拨康视云)第四次向港交所主板提交上市申请书,建银国际、华泰国际为其联席保荐人。该公司曾于2023年11月、2024年5月、2024年12月2日向港交所提交过上市申请书。招股书显示,拨康视云是一间临床阶段眼科生物科技公司,致力于开发各种疗法。眼科是研究眼部结构、功能和疾病的医学分支。拨康视云首家主要营运实体...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10